1. 1
CURRICULUM VITAE
Andrei V. Popov
Russian, married, two children
Born in Moscow, USSR, 10 August 1965
Ecrins Therapeutics SAS
BIOPOLIS, 5 av. du Grand Sablon
38700 La Tronche (Grenoble area)
FRANCE
Tel.: +33 (0) 4 76 54 95 66
Cell: +33 (0) 6 50 63 34 04
Fax: +33 (0) 4 76 54 95 68
email: andrei.popov@ecrins-therapeutics.com
http:// www.ecrins-therapeutics.com
PROFESSIONAL EXPERIENCES
Since July 2010: ECRINS THERAPEUTICS, co-founder, president and CEO
Strategy: market analysis (Drug discovery, Oncology, Life
Sciences, Pharmacology) and company positioning. Attracting
strategic public and private contracts (MESR, OSEO/BPI,
CLARA, UJF, INSERM, etc).
Finance and administration: Business Plan & Budget. Relations
with investors. Editing and submitting applications (grants,
« agréments CIR », « statut JEI »). Running the company’s
administration. HR (job definition, interviewing and hiring
personnel).
Commercial activities: market evaluation, communication,
contract negociation, editing contracts.
Results:
 Creation of a company with a capital of 106 K€; in-licensing of the
patent WO2011/107709/A1.
 Private funds raised (2015): 660 K€.
 Fundings obtained: 246 K€ grant « Concours National d’Aide à la
Création d’Entreprises Innovantes » of MESR/OSEO ; 630 K€
grant of CLARA ; 170 K€ bank loans; 105 K€ long-term loan
“PPA” (OSEO) ; 56 K€ grants from BPI ; grant Ideclic 30K€ ; A3P
COFACE 36 K€.
 Collaborative projects: EUROSTARS (2015) – 377 K€ (total
budget 1.65 M €); FUI (2015) - 400 K€ (total budget 2.2 M €).
 Creation in 2013 of the commercial branch of Ecrins
Therapeutics: Turnover (2013) 156 K€. Several international
distribution and service providing contracts signed.
2003-2010 INSERM, winner of the program AVENIR of INSERM. Staff scientist.
Research : project aiming the discovery of new regulators of cell
division and small molecules for the treatment of cancer
Running the project: teem recruitment and administration;
attracting funding, communication and publication of results,
collaborations, education (MS and PhD). Identification of
patentable inventions and editing patent applications.
Results :
 Obtained 7 public grants (600 K€)
 Published 10 peer-reviewed papers
 Named inventor on two patents
1997-2003 EMBL, Heidelberg (Germany) : postdoctoral researcher in cell biology

2. 2
Research: project aiming the discovery of novel regulators of cell
division.
Results :
 Identification and characterization of an important regulator of
microtubule cytoskeleton, necessary for the cell division (field of
application: oncology).
 Published 4 peer-reviewed papers
1994-1997 Babraham Institute, Cambridge (GB) : Visiting Scientist, Higher
Scientific Officer
Research : project aiming the production of transgenic mice
expressing the diverse repertoire of human antibodies
Results :
 Successful production of transgenic mice (team work).
 Defending PhD thesis.
 Published 12 peer-reviewed papers
 I receive fees for my participation in the creation of the intellectual
property (patent WO90/04036).
1988-1993 Medical Biotechnology Centre, Moscow, Russia. Research
Assistant
Research: biochemistry and production of monoclonal antibodies
for diverse applications
Results :
 numerous monoclonal antibodies have been obtained and
characterized
1984-1988: During my studies at the medical faculty from 1983 until graduating in 1988 I
worked as a nurse in intensive care units in several Moscow hospitals.
.
EDUCATION
2009 Business course at EM Lyon (business school) for award winners in the
“Emerging” category of the 11th
National ANRT/OSEO 2009 competition.
2008-2009 Business course for the founders of new innovative businesses at the
Grenoble business incubator GRAIN (Grenoble)
1997 PhD thesis defended in February 1997 at the Russian Haematology
Research Center, Moscow. Title of the thesis: “Studies of expression of
the human immunoglobulin lambda light chain genes in transgenic
model”. Doctoral studies carried out at Babraham Institute, Cambridge,
UK.
1988 Medical Doctor (Internal Diseases), Sechenov 1st
Medical Institute
(now Moscow Medical Academy)
EXTRA COURSES
September 1997 EMBO Practical Course on Lymphocyte Development, Basel Institute of
Immunology
.
1982-1984 Advanced French language Courses; Advanced English language
Courses.

3. 3
PERSONAL FELLOWSHIPS
2000-2003 European Molecular Biology Laboratory (EMBL) fellowship
1998-2000 Human Science Frontier Program (HFSP) long-term fellowship
1997-1998 European Molecular Biology Organisation (EMBO) long-term
fellowship
LANGUAGES Native Russian speaker. Fluent in French and English. Basic Spanish and
German.
SCIENTIFIC INTERESTS : Cell cycle and the role of the microtubule cytoskeleton. Bioactive small
molecules and pharmacology.
TECHNICAL SKILLS
(BIOLOGY)
Analytical and preparative protein biochemistry. Monoclonal antibody
production and immunochemistry. Protein expression in prokaryotic and
eukaryotic cells (baculovirus system). Cell culture and microscopy
techniques (indirect immunofluorescence, confocal microscopy, live cell
imaging etc.). Recombinant DNA techniques, phage library construction
and the standard cell and molecular biology methods. PCR, RT-PCR,
5’RACE etc. YAC technologies and YAC introduction into mammalian
cells. Xenopus laevis egg extract techniques. Anti-proliferative drug
discovery and preclinical drug development.
AWARDS  2009- winner in the “Emerging” category of the 11th National
MESR/OSEO competition for helping the creation of innovative
technologies enterprises, 27 K€.
 2010 – winner in the « Création et Developpement» category of the
12th National MESR/OSEO competition for helping the creation of
innovative technologies enterprises, 220 K€.
 2011- (together with Aurelie Juhem) laureates of Réseau
Entreprendre® contest - national French association of
entrepreneurs; personal loan to the founders of a novel business –
75 K€.
PATENTS 1. A patent titled “Production of Human Antibodies from Transgenic
Mice” (12.10.1998, GB8823 869.6/WO90/04036) has been issued to
the Babraham Institute (Cambridge, UK). These mice are being used
for production of human antibodies by companies Medarex and
Abgenix, Inc. Under the BBSRC Reward to Inventors Scheme I
receive fees for my participation in the creation of the intellectual
property.
2. A patent titled “Novel dibenzo[c,h][1,5] naphthyridines and their use
as DNA probes” has been deposed by Inserm Transfert
(Inserm/Institut Curie/CNRS/CEA), 2006. Authors: A.V. Popov, J.-C.
Florent et D. Grierson. WO 2007/096728.
3. Patent (UJF, CNRS, Institut Curie). Inventeurs : A.V. Popov, A.
Juhem, J.-C. Florent, C.-H. Nguyen. 2010, dépôt: 1/03/2010, N° de
dépôt : N° FR1000829 and WO2011/107709 A1.
4.
EDUCATION
(PhD student
management)
Aurélie JUHEM, January 2005 - 3.10.2008; EDCSV, Biologie
Cellulaire, UJF; program “Emergence”. Thesis defended on the 3d
October 2008: “Identification of a novel PP1 inhibitor with anti-cancer
properties».

4. 4
EXPERTISE  I served as referee for the following journals:: Biotechniques,
EMBO Reports, FEBS Letters,J Cell Biology, Molecular and
Cellular Proteomics, Protein Expression and Purification, J
Cell Science, RNA Biology, Cancer Letters
 I refereed patents applications for Marks & Clerk patents
attorneys (Cambridge, UK).
EXTRACURRICULAR
ACTIVITIES
Rock-climbing and mountaineering.